

Table S12. Comparison of results of selected outcomes with results from the HeLP-Diabetes trial

HED-LINE study						
	HL activators		Control		HL vs. Control	
1-year outcome	Baseline	Change from baseline to 1 year	Baseline	Change from baseline to 1 year	Mean difference (95% CI)	p Value
HbA1c, mmol/mol	62.71	-2.4	62.71	-1.1	-1.3 (-1.8; -0.9)	<0.0001
HbA1c, %	7.89	-0.2	7.89	-0.1	-0.1 (-0.2; -0.1)	<0.0001
Body mass index (BMI), kg/m ²	34.18	-0.4	34.14	-0.2	-0.2 (-0.3; -0.1)	<0.0001
Systolic blood pressure (SBP), mmHg	131.49	+0.1	131.64	+1.4	-1.2 (-1.7; -0.8)	<0.0001
Diastolic blood pressure (DBP), mmHg	78.34	-0.2	77.74	+0.8	-0.9 (-1.2; -0.6)	<0.0001
Insulin use (no baseline insulin)*	11.7%	-9.6%	14%	-11.9%	OR: 1.0 (0.8; 1.2)	0.919
Completion of eight care processes*	56.3%	+2.5%	35.8%	+8.9%	OR: 1.6 (1.5; 1.8)	<0.0001
HeLP-Diabetes trial						
	HeLP-Diabetes		Control		HeLP-Diabetes vs control	
1-year outcome	Baseline	Change from baseline to 1 year	Baseline	Change from baseline to 1 year	Mean difference (95% CI)	p Value
HbA1c, mmol/mol	56.3	-0.8	56.8	+1.8	-2.6 (-4.8; -0.5)	0.014
HbA1c, %	7.3	-0.1	7.3	+0.2	-0.2 (-0.4; -0.1)	0.014
Body mass index (BMI), kg/m ²	30.1	+0.1	30.0	-0.04	0.2 (-0.3; 0.6)	0.498
Systolic blood pressure (SBP), mmHg	134.7	-4.2	134.9	-0.5	-3.8 (-6.6; -0.9)	0.010
Diastolic blood pressure (DBP), mmHg	77.8	-2.5	77.1	-1.9	-0.6 (-2.4; 1.2)	0.519
Completion of 9 care processes*	65%	-5.1%	61%	+3.4%	OR: 0.8 (0.5; 1.4)	0.379